分行业来看，上述预增或扭亏的47股中，属于基础化工行业的最多，共7股；其次是机械设备、电子、有色金属，分别有6股、5股、4股。 6股晚间公告业绩预增 1月7日晚间，16股发布2025年度业绩相关公告，其中川金诺、泉阳泉、北方导航、高能环境、康辰药业、中科蓝讯6股业绩预增，报喜比 例为37.5%。 从预告净利润同比增幅下限来看，中科蓝讯预计增幅最高，预计实现归母净利润14亿元—14.3亿元，同比大幅增长366.51%—376.51%。公 司表示，本报告期非经常性损益主要为投资摩尔线程和沐曦股份取得的公允价值变动，较上年有大幅增长，导致公司2025年度实现归母净 利润较上年大幅增长。数据显示，摩尔线程和沐曦股份上市以来较发行价分别上涨440.37%、477.07%。 截至目前，已有67股发布2025年度业绩相关公告，其中47股实现归母净利润同比增长或扭亏，报喜比例超过七成。 从预告净利润同比增幅下限来看，中科蓝讯、百奥赛图、传化智联、康辰药业4股预告净利润同比增幅居前，均超过200%。 预计2025年度净利润增幅居前的个股 | 代码 | 简称 | 预告净利润同比 增长下限 | 申万行业 | 总市值 (亿元) | ...

Core Insights - A total of 55 companies have announced their annual performance forecasts for 2025, with 46 companies expecting profit increases, representing 83.64% of the total [1] - Among the companies forecasting profit increases, 8 are expected to see net profit growth exceeding 100%, while 12 companies anticipate growth between 50% and 100% [1] - The highest expected net profit growth is from Chuanhua Zhili, with a median increase of 308.82%, followed by Bai'ao Saitu at 303.57% and Yinglian Co. at 193.27% [1] Company Performance - Chuanhua Zhili (Code: 002010) expects a net profit increase of 308.82% with a latest closing price of 6.08 and a year-to-date increase of 4.65% [1] - Bai'ao Saitu (Code: 688796) anticipates a net profit increase of 303.57%, with a closing price of 55.05 and a year-to-date increase of 4.66% [1] - Yinglian Co. (Code: 002846) forecasts a net profit increase of 193.27%, with a closing price of 16.67 and a year-to-date increase of 3.28% [1] Industry Insights - The companies expecting to double their profits are primarily from the home appliance, machinery, and steel industries, with one company from each sector listed [1] - The average increase in stock prices for companies expecting profit doubling is 3.88%, outperforming the Shanghai Composite Index [1] - The company with the highest year-to-date stock price increase is Nanxing Co. (Code: 002757), which has risen by 10.02% [1]

1月5日，百奥赛图涨4.66%，成交额3.51亿元。两融数据显示，当日百奥赛图获融资买入额3423.52万 元，融资偿还3584.56万元，融资净买入-161.05万元。截至1月5日，百奥赛图融资融券余额合计5748.52 万元。 融资方面，百奥赛图当日融资买入3423.52万元。当前融资余额5748.52万元，占流通市值的2.91%。 资料显示，百奥赛图(北京)医药科技股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业 基地宝参南街12号院，成立日期2009年11月13日，上市日期2025年12月10日，公司主营业务涉及百奥赛 图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司 运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分 部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动 物，亦向客户授出若干模式动物的许可。抗体开发分部识别有潜力成为候选药物的抗体，并就潜在治疗 性抗体分子对外授权或与合作伙伴合作。创新药开发分部研发创新药，专注肿瘤学和自身免疫性疾病治 疗。 责任编辑：小浪 ...

证券代码：688796 证券简称：百奥赛图 公告编号：2026-001 百奥赛图（北京）医药科技股份有限 魏义良先生辞去董事职务未导致公司董事会成员人数低于法定人数，不会影响公司董事会的正常运行， 不会对公司正常经营活动产生不利影响。公司将按照有关规定尽快履行补选董事的相关程序。 魏义良先生已确认，其于任期内与公司董事会之间概无分歧。魏义良先生担任公司董事期间恪尽职守、 勤勉尽责，公司及董事会对魏义良先生在任职期间为公司发展做出的贡献表示衷心感谢。 特此公告。 百奥赛图（北京）医药科技股份有限公司（以下简称"公司"）董事会于近日收到魏义良先生提交的辞职 报告。魏义良先生因其他工作安排原因申请辞去公司董事职务。辞职后，魏义良先生不再担任公司任何 职务。魏义良先生辞职不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运作， 其辞职报告自送达公司董事会之日起生效。 一、董事离任情况 (一)提前离任的基本情况 ■ (二)离任对公司的影响 公司关于公司非执行董事离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重 ...

值得注意的是，传化智联（002010）(002010.SZ)以高达256.07%至361.57%的净利润预计增幅，暂列目前"预增王"。公司预计 2025年归母净利润为5.4亿至7亿元。公告显示，业绩大幅增长除因主营业务取得良好增长外，也受益于转让部分子公司股权确认 的投资收益及回购子公司股权提升持股比例等因素。 传统制造业在此轮业绩预告中表现尤为亮眼。钢铁行业方面，首钢股份（000959）(000959.SZ)预计2025年归母净利润为9.2亿元 至10.6亿元，同比增长95.29%至125.01%，增速上限在已披露公司中位居前列。公司表示，业绩增长得益于产品结构优化、高端 化发展及"极低成本"管理理念的贯彻。 同样属于钢铁板块的华菱钢铁（000932）(000932.SZ)在消化了补缴环保税及滞纳金约6.57亿元的情况下，依然预计净利润增长 27.97%至47.66%。对此，公司解释，主要得益于降本增效以及高端化、绿色化、智能化、精益化"四化转型等工作的开展。 以电子、医药生物为代表的高景气赛道则呈现批量报喜的态势。其中，电子行业的强一股份(688809.SH)预计净利润增长52.30% 至80.18%；医 ...

值得注意的是，传化智联（002010.SZ）以高达256.07%至361.57%的净利润预计增幅，暂列目前"预增 王"。公司预计2025年归母净利润为5.4亿至7亿元。公告显示，业绩大幅增长除因主营业务取得良好增 长外，也受益于转让部分子公司股权确认的投资收益及回购子公司股权提升持股比例等因素。 传统制造业在此轮业绩预告中表现尤为亮眼。钢铁行业方面，首钢股份（000959.SZ）预计2025年归母 净利润为9.2亿元至10.6亿元，同比增长95.29%至125.01%，增速上限在已披露公司中位居前列。公司表 示，业绩增长得益于产品结构优化、高端化发展及"极低成本"管理理念的贯彻。 同样属于钢铁板块的华菱钢铁（000932.SZ）在消化了补缴环保税及滞纳金约6.57亿元的情况下，依然 预计净利润增长27.97%至47.66%。对此，公司解释，主要得益于降本增效以及高端化、绿色化、智能 化、精益化四化转型等工作的开展。 以电子、医药生物为代表的高景气赛道则呈现批量报喜的态势。其中，电子行业的强一股份 （688809.SH）预计净利润增长52.30%至80.18%；医药行业的百奥赛图（688796.SH）则凭借海外 ...

Core Viewpoint - The A-share pharmaceutical sector in 2025 exhibits structural differentiation, with innovative drugs and CXO sectors thriving due to overseas demand and business development, while traditional Chinese medicine, medical devices, and pharmaceutical commerce face performance pressures [3][20]. Summary by Category Overall Market Performance - The A-share pharmaceutical and biotechnology sector saw an overall increase of 25.64% from January 1 to December 30, 2025, despite a slight decline in revenue and a stabilization in profits, with total revenue of 18,544.52 billion yuan, down 1.42% year-on-year, and net profit of 1,407.32 billion yuan, down 1.65% year-on-year [4][21]. Innovative Drug Sector - The innovative drug sector was a standout performer in 2025, with the chemical pharmaceutical segment rising by 32.58% and the medical services segment by 32.91% [4][21]. - Companies like BeiGene (百济神州) reported significant growth, achieving revenue of 27.595 billion yuan, a 44.2% increase year-on-year, surpassing the total revenue of 27.21 billion yuan for 2024 [4][22]. Business Development (BD) Trends - The business development landscape for innovative drug companies is evolving, with significant partnerships such as the 11.4 billion USD deal between Innovent Biologics and Takeda, and a 12.5 billion USD collaboration between Hengrui Medicine and GlaxoSmithKline [5][22][24]. - The total value of business development transactions reached approximately 94.158 billion USD in the first three quarters of 2025, significantly exceeding the total for 2024 [25]. CXO Sector Performance - The CXO sector, driven by the demand for innovative drug research, achieved a 32.91% increase in 2025, with total revenue of 1,365.72 billion yuan, up 3.63% year-on-year, and net profit of 209.12 billion yuan, up 36.47% year-on-year [10][27]. - Leading companies like WuXi AppTec (药明康德) and Kanglong Chemical (康龙化成) returned to growth, with WuXi AppTec reporting a revenue increase of 18.61% and net profit growth of 84.84% [28][31]. Traditional Chinese Medicine and Medical Devices - The traditional Chinese medicine sector experienced a modest increase of 6.75% in 2025, with total revenue of 2,590.69 billion yuan, down 4.33% year-on-year, and net profit of 294.99 billion yuan, down 1.53% year-on-year [36]. - The medical device sector reported a revenue of 1,792.10 billion yuan, down 2.24% year-on-year, with notable performance differences among sub-sectors, where companies like Mindray Medical (迈瑞医疗) showed strong overseas revenue growth [33][34].

Group 1 - The company Baosai Technology-B (02315) announced that Mr. Wei Yiliang has submitted his resignation due to other work commitments [1] - Mr. Wei's resignation will take effect on December 31, 2025 [1] - He has held the position of non-executive director and was a member of the audit committee and strategic development committee [1]

Core Viewpoint - The company announced the resignation of Mr. Wei Yiliang from his position as a non-executive director and member of the audit committee and strategic development committee, effective December 31, 2025 [1] Group 1 - Mr. Wei Yiliang is resigning due to other work arrangements [1] - The resignation will take effect at the end of 2025 [1]

百奥赛图（北京）医药科技股份有限公司 关于公司非执行董事离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 百奥赛图（北京）医药科技股份有限公司（以下简称"公司"）董事会于近 日收到魏义良先生提交的辞职报告。魏义良先生因其他工作安排原因申请辞去公 司董事职务。辞职后，魏义良先生不再担任公司任何职务。魏义良先生辞职不会 导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运作，其辞 职报告自送达公司董事会之日起生效。 一、董事离任情况 | | | | 姓名 | 离任职务 | 离任时间 | | 原定任期 | | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 到期日 | | | 股子公司任职 | （如适用） | 毕的公开 | | | | | | | | | | | 承诺 | | 魏义良 | 董事 | 2025 | 年 12 ...